Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KI-3149
- Development stage
- Preclinical
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KI-3149 is a small molecule drug candidate currently in the research phase, developed by Kuhnil Pharmaceuticals. It is primarily being investigated for the treatment of Acute Myeloid Leukemia (AML) and is also listed in development pipelines for Renal Cell Carcinoma (RCC). As a part of Kuhnil's oncology research program, KI-3149 represents an effort to develop targeted small molecule inhibitors for high-need hematologic and solid tumor indications. The specific molecular target and mechanism of action have not been publicly detailed by the developer.
Beyond the preview
Go deeper on KI-3149.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KI-3149.